DOP2011000045A - Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)

Info

Publication number
DOP2011000045A
DOP2011000045A DO2011000045A DO2011000045A DOP2011000045A DO P2011000045 A DOP2011000045 A DO P2011000045A DO 2011000045 A DO2011000045 A DO 2011000045A DO 2011000045 A DO2011000045 A DO 2011000045A DO P2011000045 A DOP2011000045 A DO P2011000045A
Authority
DO
Dominican Republic
Prior art keywords
tfpi
monoclonal antibodies
inhibitor
antibodies against
factor via
Prior art date
Application number
DO2011000045A
Other languages
English (en)
Inventor
Zhuozhi Wang
John F Murphy
Junliang Pan
Bing Liu
Haiyan Jiang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41664165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000045(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of DOP2011000045A publication Critical patent/DOP2011000045A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan anticuerpos monoclonales aislados que se unen al inhibidor de la vía del factor tisular (TFPI) humano y las moléculas de ácido nucléico aisladas que los codifican. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos monoclonales anti-TFPI y procedimientos para tratar deficiencias o defectos de la coagulación mediante administración de los anticuerpos. También se proporcionan procedimientos para producir los anticuerpos.
DO2011000045A 2008-08-04 2011-02-04 Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) DOP2011000045A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8598008P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
DOP2011000045A true DOP2011000045A (es) 2011-10-31

Family

ID=41664165

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2011000045A DOP2011000045A (es) 2008-08-04 2011-02-04 Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
DO2019000287A DOP2019000287A (es) 2008-08-04 2019-11-12 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2019000287A DOP2019000287A (es) 2008-08-04 2019-11-12 Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)

Country Status (35)

Country Link
US (3) US20120269817A1 (es)
EP (1) EP2321356B1 (es)
JP (1) JP5801194B2 (es)
KR (5) KR101769725B1 (es)
CN (4) CN110452299A (es)
AU (3) AU2009279804C1 (es)
BR (2) BR122017025538A2 (es)
CA (4) CA3081514C (es)
CL (3) CL2011000230A1 (es)
CO (1) CO6351803A2 (es)
CR (1) CR20110066A (es)
CU (2) CU23880B1 (es)
CY (1) CY1120670T1 (es)
DK (1) DK2321356T3 (es)
DO (2) DOP2011000045A (es)
EC (1) ECSP11010810A (es)
ES (1) ES2677329T3 (es)
HR (1) HRP20181095T1 (es)
HU (1) HUE038648T2 (es)
IL (4) IL210987A (es)
LT (1) LT2321356T (es)
MX (1) MX2011001351A (es)
MY (1) MY161844A (es)
NZ (2) NZ714313A (es)
PE (2) PE20110771A1 (es)
PH (1) PH12017502286A1 (es)
PL (1) PL2321356T3 (es)
PT (1) PT2321356T (es)
SG (1) SG10201703066PA (es)
SI (1) SI2321356T1 (es)
SV (1) SV2011003828A (es)
TR (1) TR201807252T4 (es)
UA (2) UA112050C2 (es)
WO (1) WO2010017196A2 (es)
ZA (1) ZA201100888B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977846B1 (ko) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
CN102325795B (zh) * 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
NZ602115A (en) * 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AU2013202745B2 (en) * 2010-03-01 2017-01-05 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2016269554B2 (en) * 2010-03-01 2018-12-20 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
MX2013011218A (es) * 2011-04-01 2013-10-17 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9556280B2 (en) 2013-03-15 2017-01-31 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
EA036490B1 (ru) * 2015-02-25 2020-11-17 Могам Инститьют Фор Байомедикал Рисерч Антитела, связывающиеся с tfpi, и содержащая их композиция
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
JP6419664B2 (ja) * 2015-08-26 2018-11-07 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
MX2021004120A (es) 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN112552396B (zh) * 2020-12-30 2022-07-12 河南中泽生物工程有限公司 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用
JP2021091720A (ja) * 2021-03-03 2021-06-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US20040052799A1 (en) * 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CA2322728A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
JP2000128803A (ja) * 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP4623825B2 (ja) * 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1282439B1 (en) * 2000-05-10 2005-11-30 Novo Nordisk Health Care AG PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US6912470B2 (en) * 2001-05-21 2005-06-28 Ecopia Biosciences, Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) * 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
CA2434323A1 (en) * 2001-02-07 2002-11-28 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
US6891085B2 (en) * 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
PL372138A1 (en) * 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003076575A2 (en) * 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
JP4460443B2 (ja) * 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10239073A1 (de) * 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
EP2853593B1 (en) * 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
RS53476B (en) * 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
DE602004026474D1 (de) * 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
EP2287179A3 (en) * 2004-01-09 2011-05-18 Novozymes A/S Increased bacillus YweA expression
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
AU2006208286A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
ES2711213T3 (es) * 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
CA2598792A1 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
ES2388932T3 (es) * 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
CN102325795B (zh) * 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
NZ602115A (en) * 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Also Published As

Publication number Publication date
US20180334509A1 (en) 2018-11-22
KR101692085B1 (ko) 2017-01-03
ECSP11010810A (es) 2011-03-31
JP5801194B2 (ja) 2015-10-28
SG10201703066PA (en) 2017-05-30
AU2009279804B2 (en) 2016-03-24
CA2933259C (en) 2021-07-06
CN110452299A (zh) 2019-11-15
MY161844A (en) 2017-05-15
KR20110043736A (ko) 2011-04-27
CL2016003015A1 (es) 2017-06-30
AU2009279804A1 (en) 2010-02-11
EP2321356A4 (en) 2013-02-13
IL250640A0 (en) 2017-04-30
CU23880B1 (es) 2013-04-19
BR122017025538A2 (pt) 2021-01-19
TR201807252T4 (tr) 2018-06-21
CY1120670T1 (el) 2019-12-11
KR20180029106A (ko) 2018-03-19
CU20110031A7 (es) 2012-06-21
ZA201100888B (en) 2012-04-25
CA2933259A1 (en) 2010-02-11
SI2321356T1 (sl) 2018-09-28
CR20110066A (es) 2011-05-25
ES2677329T3 (es) 2018-08-01
KR20160091439A (ko) 2016-08-02
KR20170005516A (ko) 2017-01-13
IL282658A (en) 2021-06-30
KR20190099341A (ko) 2019-08-26
JP2013500701A (ja) 2013-01-10
DK2321356T3 (en) 2018-07-23
WO2010017196A3 (en) 2010-11-04
CA2733075C (en) 2018-10-23
CU20110236A7 (es) 2012-07-31
US20120269817A1 (en) 2012-10-25
WO2010017196A2 (en) 2010-02-11
US20170342162A1 (en) 2017-11-30
KR101769725B1 (ko) 2017-08-18
CU23900B1 (es) 2013-03-28
EP2321356B1 (en) 2018-04-11
HRP20181095T1 (hr) 2018-09-21
PL2321356T3 (pl) 2018-10-31
CN105944100B (zh) 2019-09-17
IL210987A0 (en) 2011-04-28
CO6351803A2 (es) 2011-12-20
LT2321356T (lt) 2018-09-10
MX2011001351A (es) 2011-10-12
CN102143979B (zh) 2016-08-03
IL210987A (en) 2017-03-30
NZ731392A (en) 2018-10-26
CA3081514A1 (en) 2010-02-11
CN110437335A (zh) 2019-11-12
PH12017502286A1 (en) 2019-11-11
CL2011000230A1 (es) 2011-06-24
CA3081514C (en) 2021-12-14
CA3138035A1 (en) 2010-02-11
BRPI0917418A2 (pt) 2021-01-05
EP2321356A2 (en) 2011-05-18
AU2016201230A1 (en) 2016-03-17
IL277162A (en) 2020-10-29
AU2009279804C1 (en) 2017-01-19
DOP2019000287A (es) 2019-12-15
HUE038648T2 (hu) 2018-11-28
IL250640B (en) 2020-10-29
CN105944100A (zh) 2016-09-21
PE20110771A1 (es) 2011-10-14
CA2733075A1 (en) 2010-02-11
AU2018203753A1 (en) 2018-06-21
PT2321356T (pt) 2018-07-17
SV2011003828A (es) 2011-05-20
CL2016003014A1 (es) 2017-06-30
PE20141563A1 (es) 2014-10-24
IL277162B (en) 2021-05-31
UA120596C2 (uk) 2020-01-10
NZ714313A (en) 2017-05-26
UA112050C2 (uk) 2016-07-25
CN102143979A (zh) 2011-08-03

Similar Documents

Publication Publication Date Title
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
DOP2013000218A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
EA201200028A1 (ru) Альфа-1 мультимеры hla-g и их фармацевтическое применение
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας